Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quintiles Forms Partnering Alliance With Hedge Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Quintiles concurrently launches the NovaQuest brand to expand strategic partnering efforts.

You may also be interested in...



Lilly Taps Investment Firm To Help Fund Phase III Alzheimer’s Trials

Lilly retains ownership and control over compounds; deal frees resources for development of other pipeline molecules.

Lilly Taps Investment Firm To Help Fund Phase III Alzheimer’s Trials

Lilly retains ownership and control over compounds; deal frees resources for development of other pipeline molecules.

Quintiles Cymbalta Promotion Expenses Ramping Up; Revenue To Follow

The company expects a 500-plus person sales force hired for the Cymbalta launch to cost $6 mil.-$7 mil. a month over the quarter. A $10 mil. milestone to Lilly is also expected to "hit this quarter."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel